Signaling revealed by mapping molecular interactions: Implications for ErbB-targeted cancer immunotherapies

Clinical and Applied Immunology Reviews

Volumn 2, Issue 3, 2002, Pages 169-186

  Vereb, György ^a   Nagy, Péter ^b   Park, John W ^c   Szöllosi, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; ErbB family; Fluorescence resonance energy transfer; Herceptin ; Immunoliposomes; Lipid rafts; Receptor tyrosine kinases; Scanning nearfield optical microscopy; Trastuzumab

Indexed keywords

ANSAMYCIN DERIVATIVE; ANTHRACYCLINE; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CHOLERA TOXIN B SUBUNIT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOLIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE; RECEPTOR SUBUNIT; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CELL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RESISTANCE; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE THERAPY; HEART DISEASE; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; PEPTIDE MAPPING; PHENOTYPE; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0036625779     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1529-1049(02)00044-2     Document Type: Review

References (95)

1. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 1998;353:583-605.
2. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:F217-48.
3. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1-8.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
5. Hunter T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 1998;94:81-119.
6. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
7. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szöll″osi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999;5:255-71.
8. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
9. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-4.
10. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988;85:5394-8.
11. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343-71.
12. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8.
13. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
14. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
15. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
16. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 2000;27:20-6.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
18. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37(Suppl 1):S18-24.
19. Carraway III KL, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
20. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000;275:8641-9.
21. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 1997;16:281-94.
22. Gadella Jr. TW, Jovin TM. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol 1995;129:1543-58.
23. Nagy P, Bene L, Balázs M, Hyun WC, Lockett SJ, Chiang NY, et al. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements. Cytometry 1998;32:120-31.
24. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-5.
25. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
26. Gadella Jr. TW, Clegg RM, Jovin TM. Fluorescence lifetime imaging microscopy: pixel-by-pixel analysis of phase-modulation data. Bioimaging 1994;2:139-59.
27. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998;141:929-42.
28. Förster T. Energiewanderung und Fluoreszenz. Naturwissenschaften 1946;6:166-75.
29. Szöll″osi J, Tron L, Damjanovich S, Helliwell SH, Arndt-Jovin D, Jovin TM. Fluorescence energy transfer measurements on cell surfaces: a critical comparison of steady-state fluorimetric and flow cytometric methods. Cytometry 1984;5:210-6.
30. Damjanovich S, Vereb Jr. G, Schaper A, Jenei A, Matkó J, Starink JP, et al. Structural hierarchy in the clustering of HLA class I molecules in the plasma membrane of human lymphoblastoid cells. Proc Natl Acad Sci USA 1995;92:1122-6.
31. 5 quaternary structure of cholera toxin. EMBO J 1996;15:4246-53.
32. Vereb G, Meyer CK, Jovin TM. Novel microscope-based approaches for the investigation of protein-protein interactions in signal transduction. In: Heilmeyer Jr LMG, editor. Interacting protein domains, their role in signal and energy transduction. NATO ASI series. New York, Springer-Verlag, 1997:49-52.
33. Nagy P, Vómosi G, Bodnár A, Lockett SJ, Szöll″osi J. Intensity-based energy transfer measurements in digital imaging microscopy. Eur Biophys J 1998;27:377-89.
34. Qian X, O'Rourke DM, Fei Z, Zhang HT, Kao CC, Greene MI. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. J Biol Chem 1999;274:574-83.
35. Chen LI, Webster MK, Meyer AN, Donoghue DJ. Transmembrane domain sequence requirements for activation of the p185c- neu receptor tyrosine kinase. J Cell Biol 1997;137:619-31.
36. Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993;8:2813-20.
37. Burke CL, Stern DF. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol 1998;18:5371-9.
38. Monson E, Merritt G, Smith S, Langmore JP, Kopelman R. Implementation of an NSOM system for fluorescence microscopy. Ultramicroscopy 1995;57:257-62.
39. Kirsch A, Meyer C, Jovin TM. Integration of optical techniques in scanning probe microscopes: the scanning near-field optical microscope (SNOM). In: Kohen E, Kirschberg JG, editors. Proceedings of NATO Advanced Research Workshop: analytical use of fluorescent probes in oncology, Miami, FL. Oct. 14-18 1995. New York, Plenum Press, 1996:317-23.
40. Edidin M. Lipid microdomains in cell surface membranes. Curr Opin Struct Biol 1997;7:528-32.
41. Nagy P, Jenei A, Kirsch AK, Szöll″osi J, Damjanovich S, Jovin TM. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J Cell Sci 1999;112:1733-41.
42. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72.
43. Janes PW, Ley SC, Magee AI. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol 1999;147:447-61.
44. Kurzchalia TV, Parton RG. Membrane microdomains and caveolae. Curr Opin Cell Biol 1999;11:424-31.
45. Pralle A, Keller P, Florin EL, Simons K, Horber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 2000;148:997-1008.
46. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 1997;9:534-42.
47. Jacobson K, Dietrich C. Looking at lipid rafts? Trends Cell Biol 1999;9:87-91.
48. Hooper NM. Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol Membr Biol 1999;16:145-56.
49. London E, Brown DA. Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 2000;1508:182-95.
50. Kenworthy AK, Petranova N, Edidin M. High-resolution FRET microscopy of cholera toxin B-subunit and GPI- anchored proteins in cell plasma membranes. Mol Biol Cell 2000;11:1645-55.
51. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signalrelated kinase (ERK). J Biol Chem 1998;273:21099-104.
52. Mineo C, Gill GN, Anderson RG. Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 1999;274:30636-43.
53. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997;272:30429-38.
54. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, et al. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 1998;273:20448-55.
55. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998;16:1391-7.
56. Waugh MG, Lawson D, Hsuan JJ. Epidermal growth factor receptor activation is localized within low- buoyant density, non-caveolar membrane domains. Biochem J 1999;337:591-7.
57. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001;74:95-113.
58. Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. Manuscript in preparation, 2002
59. Vereb Jr. G, Matkó J, Vamosi G, Ibrahim SM, Magyar E, Varga S, et al. Cholesterol-dependent clustering of IL-2Rα and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc Natl Acad Sci USA 2000;97:6013-8.
60. Soltoff SP, Cantley LC. p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem 1996;271:563-7.
61. Nakamura N, Chin H, Miyasaka N, Miura O. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. J Biol Chem 1996;271:19483-8.
62. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999;274:17209-18.
63. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996;271:5251-7.
64. Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 1996;12:1117-25.
65. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-97.
66. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4:148-58.
67. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
68. Park JW, Tripathy D, Campbell DB, Esserman KJ. Biological therapy of breast cancer. Biodrugs 2000;14:221-45.
69. Szöll″osi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995;55:5400-7.
70. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-74.
71. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997;3:21-30.
72. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80.
73. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, et al. Characterization of an antip185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82.
74. Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, et al. c-Cbl is a suppressor of the neu oncogene. J Biol Chem 2000;275:35532-9.
75. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-8.
76. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14:2099-109.
77. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
78. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun 2001;280:274-9.
79. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9.
80. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2001; In press.
81. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92:1327-31.
82. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997;118:153-60.
83. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7.
84. Tikhomirov O, Carpenter G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 2000;275:26625-31.
85. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-5.
86. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int J Oncol 2001;19:811-9.
87. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994;269:23931-6.
88. Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, et al. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther 2000;7:241-8.
89. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, et al. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 1995;92:8338-42.
90. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13.
91. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001;58:114-22.
92. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
93. Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, et al. HER2/neu antisense targeting of human breast carcinoma. Oncogene 2000;19:6138-43.
94. Green DW, Roh H, Pippin J, Drebin JA. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. J Am Coll Surg 2000;191:93-105.
95. Horejsi V, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Drbal K. Signal transduction in leukocytes via GPIanchored proteins: an experimental artefact or an aspect of immunoreceptor function? Immunol Lett 1998;63:63-73.